Abstract: TH-PO911
Stakeholder Perspectives on Implementing Precision Medicine in Diabetic Kidney Disease
Session Information
- Diabetic Kidney Disease: Biomarkers, Pathogenesis
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Pena, Michelle, University Medical Center Groningen, Groningen, Netherlands
- Czaja, Julia, University Medical Center Groningen, Groningen, Netherlands
- Nabais, Joao Mv, Associação Protetora dos Diabéticos de Portugal, Lisboa, Portugal
- Cos claramunt, Francesc xavier, Primary Care Diabetes Europe, Barcelona, Spain
- Nolan, John J., European Diabetes Forum, Dublin, Ireland
- Vetter, Thorsten, European Medicines Agency, Amsterdam, Netherlands
- Kretzler, Matthias, U.Michigan, Ann Arbor, Michigan, United States
- Gomez, Maria F., Lund University, Malmö, Sweden
- Schulze, Friedrich, Boehringer Ingelheim International GmbH, Ingelheim, Germany
- de Zeeuw, Dick, University Medical Center Groningen, Groningen, Netherlands
- L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands
- Mol, Peter G M, University Medical Center Groningen, Groningen, Netherlands
Group or Team Name
- BEAt-DKD Consortium
Background
One of the important aims of the Innovative Medicine Initiative BEAt-DKD consortium is to promote implementation of Precision Medicine (PM) in treating diabetic kidney disease (DKD). Engaging stakeholders is crucial in this process. We held a consensus workshop and conducted a survey of diabetes stakeholders to identify benefits and obstacles of PM, and to strategize solutions.
Methods
Sevently-one participants from 26 countries met in Amsterdam, the Netherlands over 2 days to develop a strategy to move PM forward in DKD. Represented stakeholder groups included patients with diabetes and advocates (n=11), academia (n=18), drug regulators (n=7), health technology assessors (HTAs)(n=6), industry (n=11), and health care providers (HCPs)(n=18). A survey was developed and pilot tested prior to implementation. Respondents were asked about their opinions on needs, benefits, and obstacles for introducing PM in DKD. A consensus discussion was held to strategize solutions.
Results
Stakeholders were mostly positive for PM in DKD (Figure). HTAs least agreed, while HCPs most agreed. Obstacles and concerns for PM included data safety, time contraints, and increased burden for assessments. Keys to successful implementation of PM would be increased engagement with patients, specific training for HCPs in PM, and early collaboration between stakeholders. All stakeholders responded that quality of life outcomes would be important to assess the impact of PM.
Conclusion
Diabetes stakeholders view PM in DKD positively. Implementing PM is complex as different stakeholders have different priorities. The consensus of all stakeholders was that early engagement and aligning stakeholders goals are critical to implement PM in DKD.